Navigation Links
Enigma Signs Real-Time PCR Licences With Applera
Date:2/7/2008

PORTON DOWN, England, February 7 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics systems, announces today that it has signed license agreements with Applera Corporation.

The licenses, signed 6 February 2008, include a Real-Time Instrument Patent License Agreement and an Application Kit License Agreement. These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields.

The Real-Time Instrument Patent License Agreement covers Enigma's current and pipeline instrument platforms of fully automated, real-time thermal cyclers across the commercial market sectors of research and applied markets. This agreement also provides Enigma with an option for a license in clinical diagnostics.

The Application Kit License Agreement covers a portfolio of important patents covering reverse transcription-based methods, real-time PCR detection process and 5' Nuclease assays and compositions, for use in fields excluding human diagnostics.

Financial terms were not disclosed.

John McKinley, Chairman of Enigma Diagnostics, said: "These licenses together with Enigma's extensive portfolio of molecular diagnostic patents and unique instrument platforms confirm Enigma's leading position within the global molecular diagnostics market and underpin the launch of its instruments in 2008."

Notes to Editors:

About Enigma Diagnostics

Enigma Diagnostics Limited is a private UK based company developing the next generation of rapid diagnostic instrument platforms for the detection and identification of infectious organisms, such as bacteria and viruses, in clinical, environmental and biological samples.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based and point-of-care tests. The Company is targeting a number of multi-billion pound markets, core among which are the clinical, defence and homeland security, and veterinary markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of-care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will build an in-house sales and marketing capability to direct distribution of its bespoke products and partner with market leaders where global penetration of markets is required.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents which represent over 15 years of UK Ministry of Defence funded research. Enigma's own R&D activities have added additional patents and design rights based upon its proprietary technologies to generate a portfolio of over 45-plus worldwide patents and patent applications dedicated to real-time PCR and wider rapid technologies of which over 26 have granted status. The patents are granted in a range of core territories. Information about Enigma is available at http://www.enigmadiagnostics.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
6. Monsanto Company Signs Share Subscription Agreement With Devgen
7. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
8. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
9. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
10. Assay Designs(TM) Announces Additions to the Leadership Team
11. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... There’s a winning streak at Voxx ... Orange County Register, after winning the award last year as well. Employees nominate their ... and COO Daniel Vesely pointed to the tech company’s upbeat environment as a reason. ...
(Date:12/9/2016)... ... December 09, 2016 , ... Aditya Humad, Acting CFO of AxioMed and ... and the United States, Axiomed is now gaining interest from Silicon Valley. “It was ... Mr. Humad went on to say that, “We expect interest to continue to rise ...
(Date:12/9/2016)... , Dec. 9, 2016  A platform of ... are moving one step closer to becoming viable ... OrthoMend Research, Inc., a start-up company from ... exclusive license for these novel absorbable bone fixation ... them for commercial use. The company has leased ...
(Date:12/9/2016)... Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... is pleased to announce that Biohaven has issued today ... Haven, Connecticut (PRWEB) Dec 9, 2016 - ... announced today that the U.S. Food and Drug Administration ... covering its drug candidate BHV-0223, an orally dissolving tablet ...
Breaking Biology Technology:
(Date:11/19/2016)... -- Securus Technologies, a leading provider of civil and ... and monitoring, announced today that it has offered a ... independent technology judge determine who has the largest and ... calling platform, and the best customer service. ... what we do – which clearly is not the ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
(Date:11/14/2016)... -- xG Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, ... use in challenging operating environments, announced its results for ... hold a conference call to discuss these results on ... below). Key Recent Accomplishments ... to acquire Vislink Communication Systems. The purchase is expected ...
Breaking Biology News(10 mins):